IN2012DN03294A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03294A
IN2012DN03294A IN3294DEN2012A IN2012DN03294A IN 2012DN03294 A IN2012DN03294 A IN 2012DN03294A IN 3294DEN2012 A IN3294DEN2012 A IN 3294DEN2012A IN 2012DN03294 A IN2012DN03294 A IN 2012DN03294A
Authority
IN
India
Prior art keywords
epitope
candidate
cross
binding agent
specific binding
Prior art date
Application number
Other languages
English (en)
Inventor
J Chang Gwongjen
D Crill Wayne
Original Assignee
Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And filed Critical Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
Publication of IN2012DN03294A publication Critical patent/IN2012DN03294A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
IN3294DEN2012 2004-07-27 2005-07-27 IN2012DN03294A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59189804P 2004-07-27 2004-07-27
PCT/US2005/026672 WO2006025990A2 (fr) 2004-07-27 2005-07-27 Localisation et caracterisation d'epitopes d'enveloppe de glycoproteine de flavivirus a reactivite croisee et leurs methodes d'utilisation

Publications (1)

Publication Number Publication Date
IN2012DN03294A true IN2012DN03294A (fr) 2015-10-23

Family

ID=36000491

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3294DEN2012 IN2012DN03294A (fr) 2004-07-27 2005-07-27

Country Status (6)

Country Link
US (3) US7906292B2 (fr)
EP (1) EP1784487B1 (fr)
AT (1) ATE521627T1 (fr)
CA (1) CA2576798C (fr)
IN (1) IN2012DN03294A (fr)
WO (1) WO2006025990A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2973863C (fr) 2009-07-31 2022-05-17 Ge Healthcare Bio-Sciences Corp. Souche du virus de la fievre jaune a haut rendement avec propagation accrue dans des cellules
US9284356B2 (en) 2011-07-12 2016-03-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Identification of a west nile virus CD4 T cell epitope and use thereof
WO2013059493A1 (fr) * 2011-10-20 2013-04-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Polypeptides d'e-glycoprotéine du virus de la dengue contenant des mutations qui éliminent des épitopes immunodominants à réaction croisée
WO2014064943A1 (fr) * 2012-10-25 2014-05-01 Osaka University Peptide antigène dérivé du virus de la dengue
CA2918644A1 (fr) 2013-06-26 2014-12-31 The University Of North Carolina At Chapel Hill Procedes et compositions pour des vaccins contre le virus de la dengue
US10060924B2 (en) 2014-03-18 2018-08-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
SG11201706342PA (en) * 2015-02-09 2017-09-28 Academia Sinica An epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP4218805A1 (fr) 2015-07-21 2023-08-02 ModernaTX, Inc. Vaccins contre les maladies infectieuses
EP3364950A4 (fr) 2015-10-22 2019-10-23 ModernaTX, Inc. Vaccins contre des maladies tropicales
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
EP3468590B1 (fr) * 2016-06-13 2025-01-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Acides nucléiques codant pour des particules du type du virus zika et leur utilisation dans des vaccins contre le virus zika et des dosages de diagnostic
WO2018052549A1 (fr) 2016-09-19 2018-03-22 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Vaccins contre le virus zika
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
WO2018151816A1 (fr) 2017-02-16 2018-08-23 Modernatx, Inc. Compositions immunogènes très puissantes
WO2018152526A1 (fr) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Vaccins contre le virus zika
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
JP7572779B2 (ja) * 2017-04-26 2024-10-24 エフ． ホフマン－ラ ロシュ アーゲー 可溶性および免疫反応性のフラビウイルスｎｓ１ポリペプチド
MA50253A (fr) 2017-09-14 2020-07-22 Modernatx Inc Vaccins à arn contre le virus zika
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
CN111048154B (zh) * 2019-12-10 2023-06-06 上海药明生物技术有限公司 一种抗体表位作图的方法
EP4226154A1 (fr) * 2020-10-07 2023-08-16 Sanofi Pasteur Tests diagnostiques améliorés
US12196755B2 (en) 2021-12-02 2025-01-14 Zymeron Corporation Immunoassay platform for the serological discrimination of closely related viruses
WO2023178310A1 (fr) * 2022-03-17 2023-09-21 The University Of North Carolina At Chapel Hill Compositions comprenant des glycoprotéines e de flavivirus modifiées, leurs procédés de fabrication et d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK172110B1 (da) * 1988-04-15 1997-10-27 Gen Hospital Corp Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6869793B2 (en) * 1996-09-24 2005-03-22 Bavarian Nordic Research Institute Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
CA2331368C (fr) 1998-06-04 2009-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vaccins a base d'acides nucleiques destines a la prevention de l'infection par flavivirus
CA2894300A1 (fr) * 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services Anticorps monoclonaux se liant ou neutralisant le virus de la dengue

Also Published As

Publication number Publication date
WO2006025990A2 (fr) 2006-03-09
EP1784487A2 (fr) 2007-05-16
US9650422B2 (en) 2017-05-16
US7906292B2 (en) 2011-03-15
US20080248064A1 (en) 2008-10-09
EP1784487B1 (fr) 2011-08-24
US9000141B2 (en) 2015-04-07
ATE521627T1 (de) 2011-09-15
US20150246951A1 (en) 2015-09-03
CA2576798A1 (fr) 2006-03-09
WO2006025990A3 (fr) 2006-06-29
US20110059131A1 (en) 2011-03-10
CA2576798C (fr) 2014-09-09

Similar Documents

Publication Publication Date Title
IN2012DN03294A (fr)
ZA200803012B (en) Bitumen composition
NZ581470A (en) Sequence based engineering and optimization of single chain antibodies
MX2020001944A (es) Poblaciones de celula madre de la placenta.
UA99262C2 (uk) СПОСІБ ЗМЕНШЕННЯ КОНЦЕНТРАЦІЇ ВІЛЬНИХ Fc-ЧАСТИН В РІДИНІ, ЩО МІСТИТЬ Fc-ВМІСНИЙ БІЛОК
MY163480A (en) Sclerostin binding agents
AR060583A1 (es) Anticuerpo de c- kit humanizado
PL2452694T3 (pl) Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania
TW200723252A (en) Information processing device, information recording medium manufacturing device, information recording medium, methods thereof, and computer program
TW200701019A (en) Device specific content indexing for optimized device operation
AU2019268061A1 (en) Placental stem cell populations
ATE500503T1 (de) Cd86- und cd80-rezeptorkonkurrenztests
UA88308C2 (ru) Агент образования олеогеля, который содержит тритерпен, олеогель и способ его получения
TW200720170A (en) Work transfer system
WO2006135793A3 (fr) Obtention de proteines par ingenierie des proteines avec des environnements de contact analogues
MX2008009830A (es) Efecto del inhibidor bst2.
WO2005116252A3 (fr) Procede d'evaluation de sequences de ribonucleotides
ATE467128T1 (de) Kolloidale metallkonjugate
TW200626128A (en) Materials and methods for improving shellfish health, immunity and growth
IL191782A0 (en) Method for generating dendritic cells employing decreased temperature
GB2412921A (en) Process for the preparation of and composition of a feedstock usable for the preparation of lower olefins
Furube Restoration Works of Angkor Complex in Cambodia designated as World Heritage
PL1730153T3 (pl) Wodno-izopropanolowy solwat olanzapiny
WO2008004127A3 (fr) Procédé d'administration du tolpérisone
Campbell et al. The(pipeline) world is not enough.